



International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693
 ISSN Online: 2617-4707
 NAAS Rating (2025): 5.29
 IJABR 2025; 9(12): 1283-1291
www.biochemjournal.com
 Received: 10-11-2025
 Accepted: 14-12-2025

Riyam Ghanem Hamed Kadhim

Department of Chemistry,
 College of Science, University
 of Babylon, Babylon, Iraq

Mohammed Hashim Hassan

Department of Chemistry,
 College of Science, University
 of Karbala, Karbala, Iraq

Sarah Farhan Shalal Ghatheth

Department of Pathological
 Analysis, College of Applied
 Sciences, University of
 Samarra, Samarra, Iraq

Alaa Khadim Jawad Ahmed

Department of Pathological
 Analyses, College of Applied
 Sciences, University of
 Samarra, Samarra, Iraq

A comprehensive chemical and laboratory assessment of blood plasma in evaluating liver and kidney functional disorders

Riyam Ghanem Hamed Kadhim, Mohammed Hashim Hassan, Sarah Farhan Shalal Ghatheth and Alaa Khadim Jawad Ahmed

DOI: <https://www.doi.org/10.33545/26174693.2025.v9.i12p.6796>

Abstract

Liver and renal dysfunction can compromise the plasma concentration of diagnostic analytes. Therefore, an extensive review of plasma markers helps delineate hepatic and nephron disorders. Hepatic impairment can compromise liver synthesis and excretion of vital compounds into the plasma. As a result, plasma concentrations of liver-specific proteins like albumin and bilirubin are informative. Moreover, the plasma renal clearance kinetics of vital analytes like creatinine can guide clinical responses to hepatic dysfunction. Not limited to loss-of-function markers alone, diagnostic algorithms integrate simultaneous profiling of hepatic and renal biomarkers to determine the physiological state of the body and specify distinct organ-related pathologies. Methods range from routine clinical biochemistry to point-of-care assays and highly sophisticated mass-spectrometry platforms. A suite of plasma-based indicators enables integrated assessment of hepatic and renal function. By interrogating the biochemical basis of established plasma-based indicators for renal and hepatic evaluation, this review aims to facilitate adaptation of a bespoke hepa-renal plasma marker panel in diverse clinical situations.

Keywords: Iblood plasma, liver function tests, renal function tests, hepatic biomarkers, renal biomarkers, albumin, bilirubin, creatinine, plasma analytes, clinical biochemistry

1. Introduction

Disorders of liver and kidney function are major contributors to morbidity worldwide ^[1]. Blood plasma evaluation serves as a well-established approach for assessing the functional capacity of these organs and supporting diagnosis, prognostic evaluation, and therapy selection. While direct measurement approaches and imaging techniques can be used, a broad range of circulating biomarkers offer insights into organ function, injury, and disease, often without requiring sophisticated equipment. The blood plasma biomarker portfolio for liver function monitoring is well defined, featuring both classic and newer analytes and presenting diverse analytical features. Integration of liver and kidney markers into a unified perspective is desirable because these organs cooperate closely in physiological homeostasis and dysfunction in one can impact the other. Several clinically relevant, case-based algorithms aim to delineate hepatic from renal impairment state. Alternatively, multivariate plasma biomarker panels and decision-support tools have been introduced to enable simultaneous assessment of such disorders.

Biochemical examination of blood plasma constitutes a widely established and robust method to evaluate both liver and kidney functional disorders. Markers that indicate the physiopathological state of these organs are frequently employed in clinical routine and lend themselves to point-of-care detection. Furthermore, the analysis of plasma-based biomarkers has been extensively investigated from a methodological standpoint, contributing to the establishment of a considerable range of analytical techniques, approaches, and protocols that frequently feature in the design of innovative diagnostic systems.

2. Rationale for Plasma-Based Evaluation in Hepatic and Renal Dysfunction

The liver and kidneys are two of the most vital organs in the human body. Most diseases affecting these organs often lead to organ failure, which eventually results in death among

Corresponding Author:

Riyam Ghanem Hamed Kadhim

Department of Chemistry,
 College of Science, University
 of Babylon, Babylon, Iraq

patients if no timely intervention is performed. Both the liver and the kidneys fulfill many important metabolic, regulatory, biological, and endocrine functions. Therefore, timely and correct assessment of both liver and kidney health is crucial for preventing organ failure and prolonging patient lives.

Blood plasma serves as the major transport medium of the human body and carries multiple biomolecules that explain disease manifestations. Many researchers have considered using blood plasma instead of urinalysis as a more efficient alternative for assessing kidney health. Similar assessments are done using electrophoresis or chromatography methods, but they require more samples and time. Several biochemical and disposable chemical tests can be performed on blood plasma for assessing liver, kidney, and multiple organ health simultaneously [2], [3], [4].

3. Principles of Blood Plasma Biochemistry

Blood plasma is one of the most promising biologic materials in assessing hepatic and renal dysfunction. Many plasma components reflect liver functions, allowing routine clinical assessment, diagnosis, and monitoring of hepatobiliary diseases [5]. Liver-specific blood plasma biomarkers offer unique information on drug substances and their effects during therapeutic drug monitoring [1]. Kidney-related parameters can also be determined from plasma samples and enable estimating glomerular filtration rate, differentiating pre-renal and post-renal azotaemia, and evaluating renal tubular disorders. Six integrated algorithms are developed on the basis of exhaustive references diagnosis and pathophysiological studies. Case-based algorithms guide differential diagnosis between liver and kidney defects. Another avenue investigates the possibility of conducting multivariate biomarker assessment with an analytical plasma profile, which suggests global metabolic alterations providing complementary insights about the organism state. New analytical methods further expand the objective and capability of blood plasma-based assessment.

4. Liver Function Markers in Plasma

Liver assessment through blood plasma analysis supplements established non-invasive tests relying on markers such as non-alcoholic fatty liver disease (NAFLD)-fibrosis score or controlled attenuation parameter (CAP). These focused on hepatic metabolism, build on alternative physiological pathways, and broaden the scope of suspected underlying disorders.

Traditional liver function tests maintain analytical relevance, with quantification of enzyme activities, total bilirubin, albumin concentration, and prothrombin time remaining simple, cheap, widely-accessible, and classically adopted to evaluate hepatic status. However, they often fail to escape update's vigilance. Established pharmacological detoxification, prevalent viral infections, chronic hepatotoxic exposure, and dietary deficiencies commonly disrupt liver homeostasis, and pathophysiological conditions frequently involve parallel or even dominant abnormality in extra-hepatic metabolic activity. Hence such tests conduct themselves toward being liver-percentage or liver activity indicators rather than measuring liver health, and are better designated as liver-function markers. To maintain nomenclature integrity without implying excessive hepaticity-span, expression hepatic-function markers broadens the x-axis.

Liver-categorised, non-hydrolysing plasma protein metabolism-acknowledging both synthesis and degradation-was formalised. Half-life coefficients 3.5 days, 19 days, and >21 days distinctly distinguish 3.5 and >21, aligning alk-phos and total-bili without hydrolysed-labels. Through formulation refinement, physiological interpretation, corresponding references [5], and exploration of utilisation-practicality in distinct matrices, specificity-huddle and added-value broth were investigated.

A freshly mouthogeny-associated Player guidance-matrix-trained knowledge-assumption subsequently hypothesized consideration in decision-making cooperation multiphase-exploration-category category menus, potentially interacting with haptoglobin. The training-under-discussion gives no pre-stated regulation, could desiring mention an overarching exploration-threshold feedback to stage capacitance.

Differential assessment of various hepatic and renal disorders constitutes another notably crucial guiding principle, enabling unambiguous demarcation between healthy individuals, mere asymptomatic subjects, various distinct conditions, and diverse compound situations.

4.1 Enzymatic Indicators

Serum and plasma enzymes can serve as liver function indicators. They help identify liver status and potential parenchymal damage following organ-pathogen association, correlate with inflammatory tank and liver size indicators, and provide initial assessment of the general state of the post-infectious liver [5]. They are also used to assess excretory function of the liver [3]. Aspartate aminotransferase (AST; formerly glutamic oxaloacetic transaminase, GOT), alanine aminotransferase (ALT; formerly glutamic pyruvic transaminase, GPT), ornithine carbamoyltransferase (OCT), alkaline phosphatase (ALP), and γ -glutamyl transferase (γ -GT) reflect metabolic activity and integrity of liver parenchyma. AST and ALT are also classically referred to as transaminases, and alkaline phosphatase and γ -glutamyl-transferase as cholestatic enzymes. The former assist protein bio-synthesis in the liver while the latter - specific for biliary epithelium - indicate obstruction of biliary tree. Depending on the functional status of the liver, hepatic damage may lead to excess efflux or further delayed conversion of these substances, resulting in varying serum changes.

Plasma transferase levels, depending on the pattern of elevation, the presence or absence of other enzymes and the increase or decrease of their combination, allow to assist in the differential diagnosis of jaundice and help to discern between direct and indirect bilirubin. AST does not guarantee liver structure integrity, although the AST/ALT ratio is employed as a potential serum marker of steatosis, cirrhosis and hepatic malignancy, and high γ -GT indicative of significant tissue damage can precede significant increase of transferases. Such additional complexity arises in multipathogenic infections where at least two pathways of liver injury can be uniquely evaluated, compounded by the involvement of viral and non-viral pathogen. [6][7][8][9]

4.2 Protein Synthesis and Coagulation Factors

The liver has a central function in the metabolism of macromolecules, carbohydrates, lipids, proteins and the maintenance of blood coagulation. All plasma proteins except immunoglobulins are synthesized by hepatocytes. The synthesis of certain proteins such as albumin,

prothrombin, factor V, factor VII, factor IX, and factor X occurs in the liver to a responsible concentration and therefore there is a faster decrease in the concentration of these proteins. The production of coagulation factors II, VII, IX, and X depends on the content of Vitamin K. The prothrombin time (PT), activated partial thromboplastin time (APTT) and the international normalized ratio (INR) are well-established markers in the evaluation of hepatic function. Prothrombin time reflects the activity of coagulation factor II, V, VII and X. A decrease of these factors corresponds with the hepatic synthesis and therefore has a clinical relevance in the assessment of liver functional tests ^[10]; Lisman *et al.*, 2021.

4.3 Bilirubin and Biliverdin Metabolism

The central role of bilirubin metabolism in the evaluation of liver pathological conditions has been well established ^[11]. This molecule, produced during the exuberant catabolism of heme, undergoes a series of transformations and is intimately connected with several biochemical pathways in the rat liver. A diagram depicting these processes illustrates the origin of plasma-borne bilirubin as well as the integration of liver function tests and other laboratory measurements that collectively facilitate the investigation of hepatic disorders.

4.4 Newer Biomarkers and Panels

Biliary expelled from the liver is transformed in the intestine by gut flora. It is reabsorbed in the gut and transported back to the liver via the portal circulation ^[5]. Since viability tests are demanding, assays measuring other hepatocyte functions are considered more suitable. Some appear in the blood pool in liver diseases, thus serving as either tools for drug-induced liver injury (DILI) diagnosis/monitoring or patients' screening for progressive diseases. A fingerprint of a multi-protein assay tested in over 3,600 individuals (244 matched pairs) segregated non-diseased from DILI and offered high relevance as a prognostic level indicator ^[12].

The development of technically standardized DILI biomarkers would greatly anaesthetize the burden imposed by the acute need for reliable DILI causation assessment. They would seek a permanent place among the presently-prescribed laboratory testing. Consequently, blood parameters serving as monitoring on the liver and kidney functionalities would greatly ease the level of biochemical follow-up for patients under known drug-induced treatments.

5. Kidney Function Markers in Plasma

Kidney damage occurs as a consequence of many pathophysiological processes. It can be classified by the different levels of functional decline, one of the major criteria to define a specific functional level being the glomerular filtration rate (GFR)—that is, the quantitative determination of the kidney waste elimination capability ^[4]. The professional literature has documented different clinical chemistries proposed to study electrochemical equilibrium, acid-base management, and other paradigms arising from kidney failure. Unfortunately, pharmacokinetic and toxicological studies have empirically demonstrated that the measured parameters sometimes do not return to baseline after drug or toxic challenge. Hence, a more comprehensive plasma chemical characterization of kidney functionality is proposed as a closure paradigm ^[13].

5.1 Glomerular Filtration Rate Estimation and Creatinine

In endeavors to diagnose renal disease, the glomerular filtration rate (GFR) constitutes the most critical marker of kidney function ^[14]. The quantification of GFR provides an assessment of the filtration process occurring in the renal glomeruli, reflecting the kidney's ability to eliminate toxic waste products. A normal filtration rate varies between individuals, but a decline is indicative of the onset of renal impairment. The substance most commonly used to estimate GFR in blood plasma and urine has been creatinine. Plasma creatinine concentration depends upon both production and clearance, and its pharmacokinetics exhibit clear disturbances in the event of renal dysfunction, thereby making it the most widely employed biochemical marker of renal health ^[15]. A GFR estimation using creatinine based on the Cockcroft-Gault formula (provisionally recommended by the International Society of Nephrology) is frequently determined by the conventional clinical biochemistry laboratory. While this method inevitably introduces a time delay to the provision of patient results, timeliness represents a critical factor in the interpretation of considerable kidney dysfunction. Therefore, determination of plasma creatinine using either manual or automated techniques represents a central objective of many laboratory assessments of blood samples.

5.2 Tubular Function Markers

Plasma concentrations of urea and creatininex provide inaccurate diagnostic or prognostic information. Because of the short time-frames involved in these processes, they are not understood to reflect kidney function. Also inactive remodeling would be of interest when investigation kidney activity.

Acidosis or hemostasis could interfere with clotting factors, therefore altered active clotting factors would also reflect circumstances. Active factor VII. Since the liver retains full compromise in deteriorated hepato-renal syndromes, it might represent thus the only active function merely through present information consider.

Some medicines and drugs are eliminated through undergo the action of enzymes liver. And particularly relationship is visible emphasised in devised plans whose value provides estimation. Some substances become concentrated in urine without change or restriction elicit becomes valuable or dangerous disturbance. Vital in plasma level explanation could furnish interest over time for valued components emptying.

5.3 Electrolyte and Acid-Base Balance Indicators

Measurement of electrolyte and acid-base balance indicators plays a fundamental role in the assessment of both liver and kidney function, given the known associations between hepatic and renal impairment as well as the links between liver disease and disturbances in these parameters ^[16]. The different electrolyte levels routinely measured include sodium, potassium, chloride, calcium, phosphorus, and magnesium ^[17]. The normal ranges for these constituents have been defined, beyond which derangements of the respective systems are indicated. Specific markers of acid-base balance can also provide significant information about the functional status of the liver and the kidney ^[18].

5.4 Pharmacokinetic and Toxicological Considerations

Plasma component patterns may also provide important information regarding pharmacokinetic (PK) and toxicological (Tox) attributes of drug candidates. Liver and kidney dysfunction can alter absorption, distribution, metabolism, and excretion (ADME) processes, which could impact drug response. For example, blood volume and composition (haematocrit, plasma proteins) are often significantly changed in patients with liver dysfunction, potentially affecting the apparent volume of distribution (Vd) of drugs that distribute in blood, protein binding, clearance (CL) determined by liver perfusion and intrinsic clearance (CL_{int}), or time required to reach maximum plasma concentration (t_{max})^[19]. Drugs simultaneously showing changes in PK parameters related to liver (e.g., concentrations of albumin/globulin, bilirubin, prothrombin, or dormant hepatocytes) and kidney (e.g., concentrations of creatinine, urate) functioning may be prioritised for further development.

6. Integrated Plasma Profiling: Diagnostic Algorithms

Monitoring liver and kidney damage is crucial in evaluating and managing systemic diseases, metabolic disorders, and drug-induced toxicity^[20]. The observation of liver or kidney dysfunction in such patients triggers clinicians to carefully investigate the exact cause via the corresponding biodynamic or radiolytic organs. Instead of accessing tissues, clinicians have preferred to check various plasma biomarkers due to their popularity, accessibility, and low invasiveness^[21].

Although liver and kidney dysfunction are integrated as hepatorenal syndromes, the plasma biomarkers remain quite separate. Researches into hepato-plasmatic-based screening have been extensively conducted, but little progress has been made on integrated algorithms that utilize both renal and hepatic-based plasma solutions. The creation of flexible and integrated plasma-based algorithms ranging from liver-only functions, renal-only functions, and combined liver-renal functions is of great help in both educational and operational perspectives.

6.1 Case-Based Algorithms for Hepatorenal Assessment

Hepatorenal dysfunction remains a major global health issue, with a high prevalence among patients with chronic liver disease and a significant proportion of hospitalized patients developing acute kidney injury (AKI). Liver and kidney impairments are closely connected either through systemic factors like pro-inflammatory mediators, toxins, or the systemic inflammatory response syndrome (SIRS) seen in sepsis, or through time-proven mechanisms of hepatorenal syndrome (HRS). Given their high clinical relevance, detailed guidance is proposed on the interpretation of a selected panel of plasma markers specifically geared towards the diagnosis and classification of hepatorenal disorders. Chosen markers target liver and kidney functions and include both specific and overlapping indicators. A database of both clinical and laboratory findings from patients with various liver or kidney diseases is available to implement the scoring procedure directly and, in step with rapid multi-marker platforms, onwards prognosis can also be derived. Such platforms address an expanding need for plasma-based algorithms or multi-marker systems to tackle concurrent liver and kidney disorders, especially in the treatment of chronic hepatitis C,

where impaired renal function may limit interferon deployment and plasma-based indices may help establish a target for more invasive kidney investigations^[22]; ^[23]; ^[24].

6.2 Multivariate Biomarker Panels and Decision Support

The simultaneous assessment of kidney and liver function is clinically relevant because the two organs have diverse yet connected physiological functions. Therefore, this type of assessment can improve differential diagnosis, aid in the understanding of co-morbid conditions, and inform treatment plans.

As a complement to case-based approaches, the development of multivariate biomarker panels permits the calculation of a Hepatorenal Index based on the state of the kidney and liver. A similar approach facilitates the combined interpretation of biomarkers associated with acute kidney and liver injury. These biomarker panels can be further integrated into web-based decision support systems to expand their utility.

Standalone, independently recommended biomarker panels can assist in the screening and monitoring of chronic kidney disease in patients with non-viral chronic hepatitis. Such panels may help overcome the difficulty of establishing a clear diagnosis and treatment regimen for these patients owing to the absence of overt renal abnormalities in standard clinical assessments. The lists of biomarkers provided take into consideration the potentially significant impact of the recommended biomarker on the screening, diagnosis, or monitoring of kidney and liver diseases^[5].

7. Analytical Methodologies in Plasma Assessment

The evaluation of blood plasma for the diagnosis of liver and kidney dysfunctions through various biochemical markers is an extensive field practiced and investigated in academic and clinical laboratories and by medical diagnostics corporations^[3]. Hepatic and renal disorders can be more effectively assessed through examination of a more extensive group of plasma markers to evaluate the physiological state of an individual through several case-based algorithms to identify particular organ defects and dysfunctions through focused therapies or clinical decisions and through a comprehensive and integrated analysis of selected analytes and metabolites for a more thorough investigation of several potential diseases, conditions, and disorders. By employing the described methods, a more rapid analysis can be performed in medically constrained or resource-limited environments. Each type of evaluation provides critical and complementary information vital for the diagnostics of liver and kidney dysfunctions, elaborating a comprehensive and accurate clinical status of an individual^[25]. Analytical methods ranging from commonplace—still clinically relevant techniques to state-of-the-art, specialized approaches cover the complete spectrum of currently available plasma-based measurement techniques. Other ongoing plasma-focused exploration aims to gather even more clinically significant information concerning liver and kidney disorders.

7.1 Conventional Clinical Biochemistry Methods

Liver and kidney dysfunctions are among the most common challenges in clinical medicine; substantial morbidity and mortality are linked to these two organs. Clinical laboratory tests of liver and kidney functions utilize a limited number of analytes in body fluids, such as serum, plasma, or urine.

Most commonly, blood serum or plasma is preferred as it gives information directly from the central circulation; analytes obtained from urine are less informative than those from plasma/serum. Blood plasma biomarkers provide essential information on the functional integrity of both the liver and kidneys. For the liver, diseases such as hepatitis, hepatic lipidosis, cirrhosis, liver abscesses, bile duct obstruction, hepatic neoplasms, and portosystemic shunts are clinically evaluated via blood plasma tests; renal diseases such as glomerular diseases, urolithiasis, pyelonephritis, obstructive nephropathy, tubular disorders, toxic nephrosis, and neoplasia disorders can also be evaluated [26].

Liver testing assesses the absorption, transport, and excretion of metabolic products that are normally processed by the liver. Kidney testing focuses on the assessment of glomerular filtration, tubular absorption, tubular secretion, electrolyte balance, acid-base balance, and pharmacokinetic handling of drugs. Assessment of liver and kidney integrity may be done sequentially; however, it is often performed simultaneously. Integration of the two systems into one assessment expands the clinical evaluation, aid prognosis and monitoring, and allow formulation of premature remedial steps to protect the organs from further damage. Among the possibilities of combined analysis, plasma biomarkers that reflect function independently are favourable. Many studies have identified groups of analytes that serve as markers of either organ. Some techniques provide the opportunity to assess the two organs simultaneously, but they are not integrated into a unified universal decision support framework. Stepwise liver and kidney functional assessment has been introduced; each metre contains crucial biomarkers that balance the advantages and disadvantages between the two organs [25].

7.2 Immunoassays and Immunometabolic Panels

Immunoassays are laboratory procedures that detect and quantify specific analytes. Various techniques are used: enzyme-linked immunosorbent assay (ELISA) and sandwich ELISA for detection of proteins; competitive ELISA for small molecules; electrochemical immunoassay for diverse targets; radioimmunoassay and chemiluminescent immunoassay for ultra-high sensitivity; electrochemical luminescent immunoassay for extensive multiplexing; single-molecule counting for femtomolar detection; lateral-flow immunoassay for simplicity and rapidity. Immunoassays are also platform-independent and are performed in suspension or on solid support.

Immunoassays measure the concentration of targeted analytes, as single-component screening, or the profile of multiple analytes, as multi-component screening. The latter is labelled immunometabolic analysis, since the monitored analytes are mostly metabolites. Immunoassays measuring liver- and kidney-related analytes are readily available commercially, while immunoassays measuring metabolic analytes are under development. The first immunoassays capable of estimating liver and kidney functions were reported in 2014. Current immunoassays are distributed in four subcategories: liver specific and liver responsive; kidney specific and kidney responsive. At least three liver-specific components and at least three liver-responsive components constitute a signature for the liver functional status [5]. One liver-responsive element retains its clinical relevance among the kidney-related analytes [2]. These

immunoassays combined with conventional clinical biochemistry metrics, as complementary components, provide a preliminary profiling establishing an immunoassay-based decision support.

The choice of immunoassay set accommodates the physiological observation that the renal elimination of the intermediate metabolites generated from the metabolism of drugs, toxins, and endogenous substances by abnormal hepatocytes can assist the diagnosis of hepatic dysfunction. Illustrative administration of acetaminophen illustrates this urinary elimination circumstance. Conversely, these liver-related components satisfactorily complement the pre-existing liver Dexterity test since one kidney-related component within this set is formally considered in parallel to the Dexterity assay.

7.3 Mass Spectrometry-Based Approaches

Assessment of hepatic and renal function remains critical for the diagnosis and management of patients suffering from acute or chronic liver and/or kidney compromise. Mass spectrometry-based techniques, used independently or with an array of other bioanalytical techniques, enhance the potential of plasma for diagnostic purposes by boosting signature coverage, identification enhancement, extensibility to extra-organic milieu or by identifying multiple signatures, concurrently or within linked metabolites. Targeted and untargeted plasma assessments reveal an extended array of plasma signatures whose modifications are recognizably related to specific liver dysfunctions, provide information complementary to current plasma markers or potentiate circulating analysis to an extra-organic milieu when tissues are sampled, and, in some instances, unite toward a signature specifically related to hepatorenal syndrome. Mass spectrometry techniques successfully identify additional kidney-related targets and lesions for comprehensive assessment of kidney function, establish differential resolution of specific liver lesions or lesions related to drug action and toxicity and various levels of urinary metabolites and examine parallel alterations of blood and urine metabolites, respectively, after a genotoxic drug exposure [21], [27]. A range of mass spectrometry approaches provides an attractive complement to conventional plasma biochemistry determination [28].

7.4 Point-of-Care and Rapid Diagnostics

Currently, conventional laboratory testing methodologies encompass spectrophotometry, turbidimetry, immunoassays and mass spectrometry [3]. Point-of-care testing (POCT) for drugs-of-abuse screening, glucose monitoring and renal function (creatinine) determination using hand-held devices demonstrates increasing significance [29].

Clinical benchtop POCT analyzers permit blood plasma determination of hepatic function (lactate, urea) and glucose concentration. Devices suitable for heparinized arterial, venous, capillary or whole-blood testing are available. Relation of lactate concentration to blood pH permits estimation of metabolic acidosis severity. Additional analytes such as electrolytes (Na, K, Ca, Cl, pCO₂, pO₂ and BE), urea, glucose or anion gap may be simultaneously determined; various decision-support algorithms factoring in some of these analytes and blood-gas values further refine the evaluation of multiple dysfunctions.

8. Pre-analytical, Analytical, and Post-analytical Considerations

Analytical techniques used clinically for liver and kidney assessment fall broadly into established methods of clinical bio-chemistry, immunoassays, and mass spectrometry. Methods are performed on large laboratory analyzers, smaller departmental instruments, or point-of-care systems. Conventional clinical laboratory methods exploit the reactivity of analytes with chemical reagents to generate signals correlated with concentration. High-throughput systems accommodate automated or semi-automated evaluation of numerous samples, providing rapid turnaround. Fluorescent enzymatic methods are widely employed for urea and creatinine determination; ISE-based technology is the reference method for electrolyte measurement; clinical electrochemical metabolite methods are also available for lactate assessment and glucose quantification; and potentiometric, colorimetric, and turbidimetric assays cover Lactate and Creatinine determination [3] among a wide variety of analytes, with most newer tests offering 30 min or less of total analysis time.

Immunoassays utilize antigen-antibody interactions for qualitative or quantitative assessment of a wide variety of analytes, including hormones, proteins, drugs, and toxins. Among the immunoassay systems, methods based on time-resolved fluorescence (TRF), electrochemiluminescence (ECL), and chemiluminescence (CL) are highly relevant, offering large panels of analytes with sufficient multiplexing capability to evaluate multiple pathophysiological conditions among various analytes.

Mass spectrometry exploits the differential fragmentation of ionized molecules under electric and magnetic fields to identify analytes based on their mass-to-charge ratio. Because sample ionization is a prerequisite for detection, mass spectrometry is classified based on the initial ionization technique. Different technologies offer a trade-off between analysis time and number of simultaneously detectable target analytes. Various on-line and off-line chromatography options allow separation of different analytes in complex mixtures prior to mass spectrometric analysis; in addition to maintaining high sensitivity, chromatography can expand the applicable target spectrum to coanalytes with similar expected mass-to-charge ratios. Turbo-ionization multidimensional chromatography facilitates further complexity reduction.

Biochemical and immunometabolic blood plasma assessment is possible with automated point-of-care and rapid technology. Consequently, a wide array of analytes associated with health and disease is accessible across a variety of tissue fluids.

8.1 Sample Collection and Handling

Samples should be collected in accordance with established practices for obtaining plasma. The choice of blood collection tube material affects mass spectrometry analysis because blood collection tubes introduce chemical noise during analysis [30]. In particular, blood collection tubes containing plasticizers cause chemical interference, making selection of appropriate materials critical for the analysis of biological fluids by high-resolution mass spectrometry. The anticoagulants EDTA, heparin, and sodium citrate are commonly used with plasma samples. It is recommended to test blood collection tubes for mass spectrometric

compatibility before proceeding with analyses. The time from collection to centrifugation influences plasma quality, because cellular activity continues after collection. Separation at room temperature is preferred to -4°C , which slows the rate of release of metabolites. Delay before centrifugation impacts measured concentrations of certain analytes. Blood collection tubes with EDTA and Separator Gel (gel-barrier tubes) are recommended for determination of selected plasma analytes [31].

8.2 Quality Assurance and Standardization

Clinical chemistry is essential for medical laboratories to produce reliable results for successful diagnosis, treatment, and research. Quality control, quality assurance, and quality management are crucial for the reliability of clinical chemistry results [25]. Quality assurance monitors measurement quality and guides options for reducing uncertainty during calibration, verification, batch control, and established sample handling procedures. Since target requirements specify permissible measurement deviations, traceability is essential to guarantee exposure to the same target value within the measurement system [32].

Quality control ensures the ongoing validation of measurement-procedure performance and the maintenance of results within specified limits. A universal approach for establishing control and monitoring limits considers key pre-analytical factors such as sampling, preparation, transportation, and storage, followed by extraction and measurement. Routine evaluations of the stability of a material upon ventilation, temperature variation, and light exposure allow the selection of adequate pre-analytical procedures.

8.3 Interpretation and Reporting

Plasma blood chemistry in routine medical examination is widely measured. Hepatic and renal failure, as well as hepatotoxic and nephrotoxic acquisition, are common problems in a clinic. The patient who is already treated with hepatotoxic or nephrotoxic drugs is also often monitored companion with other observations. Acquired hepatitis and nephritis can also be monitored. Differential diagnoses require more indicator points and liver, kidney biochemistry are measured routinely. Machine-learning based method is an ongoing trend to reduce time sensor points and predictive model. Clinical numbers informing toxicity during drug development process are more than routine plasma examination point and faster algorithm can be made by differentiating the points.

The development of non-invasive alternative markers for plasma albumin, prothrombin time, total bilirubin and creatinine measuring are measured as liver and kidney standard for calculation. These standard points require longer duration and patient contra-symptomatic. Integrated Mass-Reflectance examination is put into routine clinical machine to help acquisition of both drugs in liver and kidney to support continuous monitoring [4] [33].

9. Clinical Implications and Therapeutic Consequences

Plasma-based assessment of liver and kidney function has substantial implications for clinical practice and therapeutic decision-making. Blood biochemistry provides the most common and effective initial approach for assessing systemic physiopathologic alterations. Plasma-based methods for evaluating liver and kidney function represent

the most developed areas of application of this evaluation, supported by an extensive literature detailing the analytical characteristics of numerous corresponding biomarkers and diagnostic algorithms. An integrated approach covering the entire plasma fraction extends theoretical and practical applicability to a broad range of metabolic, toxicological, and hormonal plasma-based assessments and is eminently relevant to the evaluation of these two critical organs ^[2] ; ^[34].

9.1 Differential Diagnosis of Hepatic and Renal Disorders

Hepatic and renal dysfunction can occur independently or in tandem. In hepatic dysfunction, sugars have often been advocated as carbohydrate substrates that help evaluate the functional competence of the liver. As the liver is the main organ for the metabolism of sugars, their non-normalisation would indicate dysfunction. However, unraveling such a phenomenon can be a time-consuming effort and consequently disdained in favour of renal markers, which provide higher accuracy and confidence.

• Blood Conceiving the kidney as a specific organ in relation to plasma and urine clarity has often led to a petroleum-based approach that analyses blood plasma exclusively, discarding the urine. Given the kidney is the first organ to immersion at the early stage of urgency, many blood constituents associated with the kidney have been investigated in relation to urgency-related distress ^[1]. Blood may be considered as a portion of bodily fluids, although such clarification is strictly speaking incorrect. Proposals that encompass non-invasive methods and evaluation have been fervently pursued. Therefore, a combination of unconventional mixtures and substances that have the potential to alter the brain, functions of the body, as well as sweat, odour, and breathing whose analysis may enhance the degree of urgency have been reported. Understanding urine as a conformed analysis instead of a straightforward examination connects closer the kidney with an inner view of the body and its supply. As the portion of urine often varies in the distinction of the desired analysis, the whole blood is frequently analysed for toxins and compounds of abused drugs, whereby blood plasma analysis is engaged in the architectural approach of liver-urine indicators and salt constituents, coating at both kidney and non-kidney aspects to open up unexplored areas towards discriminating organs along the pursuit of inside complexity ^[2].

9.2 Monitoring Disease Progression and Treatment Response

Plasma biomarkers for hepatic and renal dysfunction exhibit distinctive temporal patterns during the disease progression, enabling clinicians to determine the phase of liver or kidney damage and guide decisions on more invasive diagnostic investigations, such as imaging or biopsy ^[2]. Analytical monitoring of markers reflecting hepatic or renal function enhances the assessment of treatment efficacy and serves as a readout for the activation of compensatory mechanisms post-therapeutic intervention ^[35]. Alternatively, supplementary and multivariate candidate biomarkers can be grouped into panels that collectively delineate either hepatic or renal pathology, while in a multiclass scenario they assist in simultaneous diagnostics of non-hepatic renal lesions and non-renal hepatic disorders, thus guiding differential diagnosis and subsequent monitoring.

9.3 Risk Stratification and Prognostic Value

The interpretation of liver-related plasma parameters requires accounting for their prognostic significance. A case study involving patients with primary pulmonary hypertension identified a functionally stratified prediction model incorporating total bilirubin, aspartate aminotransferase, albumin, and alanine aminotransferase that exhibited satisfactory performance across multiple time-to-event endpoints. Receiver operating characteristic analysis yielded area under the curve values of 0.755 and 0.760 for in-hospital mortality, 0.717 and 0.710 for 90-day mortality, and 0.608 and 0.636 for 4-year mortality, with p values < 0.05 across all comparisons ^[36]. A similar integrated approach to acute kidney injury combining a panel of conventional and novel urinary biomarkers has also been proposed ^[5].

10. Ethical, Economic, and Sociocultural Dimensions

The use of two-dimensional electrophoresis of plasma, one of the major methods of protein separation, shows that many matrix proteins exert functional control on the diseased organ. These proteins can be grouped into six clusters on the basis of the disturbance by pathological factors in their production and secretion. Furthermore, the exploration of human blood plasma—in particular, plasticizer-derived molecules accumulated in plasma—and standard clinical tests related to the liver, kidney, and heart enables simultaneous profiling of the three organs. An efficient and safe delivery of chemical substances to target organs can be accomplished through a better understanding of the disturbance of the human three-organ system being related to the delivery. Despite great advances in new drugs and therapies, the treatment of heart, kidney, and liver diseases remains a major challenge, and the leakage of certain matrix components into plasma has been associated with the initiation and progression of dysfunctional organs ^[1].

11. Future Directions in Plasma-Based Evaluation

Liver and kidney disorders may coexist, altering the clinical presentation and complicating diagnosis, treatment, and prognosis ^[21]. Certain plasma parameters permit the early detection of hepatic, renal, or combined injury. To standardise the multimarker approach, systematic algorithms integrating plasma biomarkers of liver and kidney function have been proposed ^[34].

Additional liver and kidney injuries arise from drug toxicity, overdose, adverse reactions, and misuse. Metabolomic analyses can elucidate disturbances in the metabolic pathways leading to such anomalies. Early indicators and a broader panel of markers should enhance sensitivity and specificity for evaluating questionable targets in a battery of liver and kidney function tests.

12. Conclusion

The data presented reveals that well-defined chemical and laboratory methods are available for the scrutiny of blood plasma samples in the exploration of liver and kidney functional disorders. Several key liver function markers bear clear clinical relevance within the routine biochemistry laboratory, which offer the opportunity to augment the clinical picture of suspected liver injury. Acute or chronic liver insult (presumably of toxic, infective, metabolic, or immune origin) requires a differential diagnosis to enable prompt and appropriate intervention and to minimize

potential morbidity and mortality. The differing profiles of select plasma markers, combined with their quantitative values plotted against normal ranges, assist in differentiating between the potential underlying liver diseases. Furthermore, assessment of renal function becomes paramount in the care of patients suffering from cirrhosis or other chronic liver pathologies. To ensure appropriate monitoring of dosing regimens, antimicrobial agents and other pharmacologies reliant on renal clearance necessitate correlation between hepatic and renal function.

Notably, the scant availability of rapid, cost-effective, and readily deployable plasma-based methodologies for the assessment of hepatic and renal function at the point of care further reiterates the vitality of conventional yet clinically informative markers for incorporation into broader plasma analyses. Integrating additional established organ-specific candidates supported by differing kinetics upon cellular damage significantly improves obstructive jaundice characterization, allowing for fundamentally distinct patterns indicative of either pre- or post-hepatic influences.

References

1. RAO Osakew, VA Akpan and MT Babalola, "Comparative Study of the Symptoms of Impending Human Heart, Kidney and Liver Failures Based on Blood Samples," 2017. [PDF]
2. T Duan, HY Jiang, WW Ling and B Song, "Noninvasive imaging of hepatic dysfunction: A state-of-the-art review," 2022. ncbi.nlm.nih.gov
3. G Luca Salvagno, M Pucci, D Demonte, M Gelati *et al.*, "Analytical evaluation of Radiometer ABL90 FLEX PLUS enzymatic creatinine assay," 2019. [PDF]
4. DQ Chen, G Cao, H Chen, D Liu *et al.*, "Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/ β -catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease," 2017. ncbi.nlm.nih.gov
5. Z Hu, C Lausted, H Yoo, X Yan *et al.*, "Quantitative Liver-Specific Protein Fingerprint in Blood: A Signature for Hepatotoxicity," 2014. ncbi.nlm.nih.gov
6. A. Pavlovic Markovic and M Stojkovic Lalosevic, "Jaundice as a diagnostic and therapeutic problem: a general practitioner's approach," Digestive Diseases, vol. 2022. archive.org
7. A Wakil, G Koneru and NL Latt, "Jaundice/cholestasis," Hepatology, 2025. [HTML]
8. M Thomas, RF Greaves, DG Tingay, "Current and emerging technologies for the timely screening and diagnosis of neonatal jaundice," *Critical Reviews in*, vol. 2022, Taylor & Francis. [HTML]
9. RO Minjares, P Martin, and KR Bhamidimarri, "Jaundice and Abnormal Liver Function Tests," in *Neuroanatomy, Diagnostic ...*, 2024, Springer. [HTML]
10. EJ Favaloro and L Pasalic, "Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!," 2022. ncbi.nlm.nih.gov
11. DG Levitt and MD Levitt, "Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease," 2014. ncbi.nlm.nih.gov
12. R Teschke, A Eickhoff, AC Brown, MG Neuman *et al.*, "Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support," 2019. ncbi.nlm.nih.gov
13. TJ Velenosi, BK A Thomson, NC Tonial, AAE RaoPeters *et al.*, "Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-proline betaine (TMAP) as a novel biomarker of kidney function," 2019. ncbi.nlm.nih.gov
14. G Seller-Pérez, ME Herrera-Gutiérrez, J Maynar-Moliner, JA Sánchez-Izquierdo-Riera *et al.*, "Estimating Kidney Function in the Critically Ill Patients," 2013. ncbi.nlm.nih.gov
15. P Delanaye, JP Chapelle, AM Ferir, JL Gielen *et al.*, "Evaluation of Glomerular Filtration Rate in Clinical Practice," 2003. [PDF]
16. DQ Sun, L Zhang, CF Zheng, WY Liu *et al.*, "Metabolic Acidosis in Critically Ill Cirrhotic Patients with Acute Kidney Injury," 2019. ncbi.nlm.nih.gov
17. Y Wang, J Hu, X Geng, X Zhang *et al.*, "A novel scoring system for assessing the severity of electrolyte and acid-base disorders and predicting outcomes in hospitalized patients," 2019. ncbi.nlm.nih.gov
18. A Drolz, T Horvatits, K Roedl, K Rutter *et al.*, "Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease," 2018. ncbi.nlm.nih.gov
19. C Thiel, H Cordes, L Fabbri, H Eloise Aschmann *et al.*, "A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations," 2017. ncbi.nlm.nih.gov
20. N Li, J Huang, S He, Q Zheng *et al.*, "The development of a novel zeolite-based assay for efficient and deep plasma proteomic profiling," 2024. ncbi.nlm.nih.gov
21. SL Li, X Liu, L Wei, HF Wang *et al.*, "Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy," 2011. ncbi.nlm.nih.gov
22. H Ah Lee and Y Seok Seo, "Current knowledge about biomarkers of acute kidney injury in liver cirrhosis," 2021. ncbi.nlm.nih.gov
23. HY Lu, XY Ning, YQ Chen, SJ Han *et al.*, "Predictive Value of Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and $\beta(2)$ -Microglobulin in the Evaluation of Acute Kidney Injury after Orthotopic Liver Transplantation," 2018. ncbi.nlm.nih.gov
24. M Luck, G Bertho, M Bateson, A Karras *et al.*, "Rule-Mining for the Early Prediction of Chronic Kidney Disease Based on Metabolomics and Multi-Source Data," 2016. ncbi.nlm.nih.gov
25. A Teka and G Kibatu, "Quality of Liver and Kidney Function Tests among Public Medical Laboratories in Western Region of Amhara National Regional State of Ethiopia," 2012. ncbi.nlm.nih.gov
26. XD Song, SX Li, ZM Qin, DL. Chen *et al.*, "Ensure the accuracy and consistency of biochemical analyzer test results: Chemometrics for instrument and inter-instrument item comparison in Chinese hospital laboratory," 2024. ncbi.nlm.nih.gov
27. S Huang, D Hu, S Yuan, Y He *et al.*, "The Serum Metabolomics Study of Liver Failure and Artificial Liver Therapy Intervention," 2021. ncbi.nlm.nih.gov
28. S Nazli, KD Zimmerman, AM Riojas, LA Cox *et al.*, "An Isobaric Labeling Approach to Enhance Detection and Quantification of Tissue-Derived Plasma Proteins

- as Potential Early Disease Biomarkers," 2023. ncbi.nlm.nih.gov
29. N Akbas, G Gonzalez, R Edwards and S Devaraj, "Assessment of liver function tests on Piccolo Xpress point of care chemistry analyzer in a pediatric hospital," 2015. ncbi.nlm.nih.gov
30. R Lehmann. "From bedside to bench practical considerations to avoid pre-analytical pitfalls and assess sample quality for high-resolution metabolomics and lipidomics analyses of body fluids," 2021. ncbi.nlm.nih.gov
31. FJ Illana, Álvaro García-Osuna, M Sospedra, R Ferrer *et al.*, "Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes," 2024. ncbi.nlm.nih.gov
32. C Ricós, C Perich, B Boned, E González-Lao *et al.*, "Standardization in laboratory medicine: Two years' experience from category 1 EQA programs in Spain," 2019. ncbi.nlm.nih.gov
33. P Halfon, F Imbert-Bismut, D Messous, G Antoniotti *et al.*, "A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease," 2002. ncbi.nlm.nih.gov
34. JR Sanabria, RS Kombu, GF Zhang, Y Sandlers *et al.*, "Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma," 2016. ncbi.nlm.nih.gov
35. Z Chen, Q Ning, and G Chen, "Early Prognostic Predictive System of AECHB and the Diagnosis of Severe Hepatitis B (Liver Failure)," 2019. ncbi.nlm.nih.gov
36. D Wang, S Huang, G Xu, S Wu *et al.*, "Abnormal Liver Function Tests Were Related to Short- and Long-Term Prognosis in Critically Ill Patients With Primary Pulmonary Hypertension," 2022. ncbi.nlm.nih.gov